Sarepta Therapeutics Inc (SRPT)

46.61
0.84 1.80
NASDAQ : Health Care
Prev Close 45.77
Open 45.75
Day Low/High 45.26 / 46.86
52 Wk Low/High 8.00 / 41.97
Volume 918.43K
Avg Volume 2.65M
Exchange NASDAQ
Shares Outstanding 64.33M
Market Cap 3.01B
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Watch the Key Technical Levels

Watch the Key Technical Levels

If they are breached, that will trigger more aggressive selling.

Sarepta Therapeutics Announces Its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data In Nature Communications

Sarepta Therapeutics Announces Its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data In Nature Communications

Data show for the first time a systemic therapeutic effect in DMD dogs using a rAAV2/8 micro-dystrophin gene therapy approach without immunosuppressive treatment

Net Seller, but Itching to Put More Cash to Work

Net Seller, but Itching to Put More Cash to Work

This is pretty typical Fed Day action, when traders do some quick trades while they wait.

Biotech Movers: Sarepta, Inovio, Mylan

Biotech Movers: Sarepta, Inovio, Mylan

Sarepta Therapeutics, Inovio Pharmaceuticals and Mylan were among the biotech movers in premarket trading on July 20.

Sarepta Therapeutics And Clinigen Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

Sarepta Therapeutics And Clinigen Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

The MAP will be available to a limited number of patients who meet pre-specified medical criteria and can secure funding

Sarepta Therapeutics And BioMarin Pharmaceutical Inc. Announce Execution Of A Global Settlement And A License Agreement Resolving Exon Skipping Patent Litigation

Sarepta Therapeutics And BioMarin Pharmaceutical Inc. Announce Execution Of A Global Settlement And A License Agreement Resolving Exon Skipping Patent Litigation

Agreement terms resolve global patent proceedings regarding Sarepta's sale of EXONDYS 51® (eteplirsen) and future Duchenne muscular dystrophy (DMD) exon-skipping products

Biotech Movers: Akebia Shares Down After Pricing Stock Offering

Biotech Movers: Akebia Shares Down After Pricing Stock Offering

Akebia Therapeutics, Sarepta Therapeutics and Esperion Therapeutics were among the biotech stock movers in premarket trading on June 29.

Sarepta Therapeutics Appoints Douglas S. Ingram As President And Chief Executive Officer

Mr. Ingram was the President of Allergan, Inc.

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On

The S&P 500 and Dow slip on a crude oil slump.

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens

Stocks are mixed as energy lags, health care leads.

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of Its Investigation Of Sarepta Therapeutics, Inc.

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating Sarepta Therapeutics, Inc.

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?

TheStreet Quant Rating: D- (Sell)